Literature DB >> 7579345

Cyclin D3 is essential for megakaryocytopoiesis.

Z Wang1, Y Zhang, D Kamen, E Lees, K Ravid.   

Abstract

A normal cell cycle in most eukaryotic cells consists of a tightly regulated sequence of phases including DNA synthesis (S) followed by a gap (G2), mitosis (M), and a gap (G1). In the megakaryocytic lineage, the cells undergo endomitosis, which involves DNA synthesis in the absence of mitosis, thus giving rise to polyploid cells. We aimed at defining whether the megakaryocytic cell cycle consists of a continuous S phase or of G1/S phases and at determining which cyclins are involved in this process. Studies were performed in primary cultures of mouse bone marrow cells. DNA synthesis in megakaryocytes was followed by determining incorporation of a DNA precursor, bromodeoxyuridine (BrdU), into the cells by in situ staining for BrdU. These experiments showed that no more than 15% of the recognizable megakaryocytes in normal bone marrow are in the process of endomitosis, including S phases interrupted by short gaps. Using immunohistochemistry, we showed that mature megakaryocytes express the G1 phase cyclin and cyclin D3, but not the mitotic cyclin, cyclin B1. Under culture conditions that selectively promote megakaryocytopoiesis, antisense oligonucleotides designed to suppress cyclin D3 expression, but not sense oligonucleotides or antisense oligonucleotides to cyclin B1, dramatically suppress endomitosis and abrogate megakaryocyte development. Our results indicate that endoreduplication in megakaryocytes is associated with low levels of or the absence of cyclin B1, whereas progression through this process depends on the G1 phase for which cyclin D3 is crucial.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579345

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  New roles for cyclin E in megakaryocytic polyploidization.

Authors:  Alexia Eliades; Nikolaos Papadantonakis; Katya Ravid
Journal:  J Biol Chem       Date:  2010-04-14       Impact factor: 5.157

2.  Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization.

Authors:  Andrew G Muntean; Liyan Pang; Mortimer Poncz; Steven F Dowdy; Gerd A Blobel; John D Crispino
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

3.  Reprogramming the cell cycle for endoreduplication in rodent trophoblast cells.

Authors:  A MacAuley; J C Cross; Z Werb
Journal:  Mol Biol Cell       Date:  1998-04       Impact factor: 4.138

Review 4.  The evolving role of the aryl hydrocarbon receptor (AHR) in the normophysiology of hematopoiesis.

Authors:  Stephan Lindsey; Eleftherios T Papoutsakis
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

5.  A role for cyclin D3 in the endomitotic cell cycle.

Authors:  J M Zimmet; D Ladd; C W Jackson; P E Stenberg; K Ravid
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

6.  The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3.

Authors:  Luke F Peterson; Anita Boyapati; Velvizhi Ranganathan; Atsushi Iwama; Daniel G Tenen; Schickwann Tsai; Dong-Er Zhang
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

7.  Tescalcin is an essential factor in megakaryocytic differentiation associated with Ets family gene expression.

Authors:  Konstantin Levay; Vladlen Z Slepak
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis.

Authors:  Wei Tong; Harvey F Lodish
Journal:  J Exp Med       Date:  2004-08-30       Impact factor: 14.307

Review 9.  Molecular control of megakaryopoiesis and thrombopoiesis.

Authors:  Itaru Matsumura; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

10.  STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice.

Authors:  Zan Huang; Terri D Richmond; Andrew G Muntean; Dwayne L Barber; Mitchell J Weiss; John D Crispino
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.